ArticleClinicoEconomics and outcomes research : CEOR2016

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US.

Jeffrey D Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.